https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17031 8. Three percent had an Index of <4, placing them in the high risk category for disease. On average, adolescents from low or medium socioeconomic communities had a significantly lower omega-3 Index compared to those from higher socioeconomic neighbourhoods (mean difference=1.4, p=0.018). Overall 20% of boys and 17% of girls reported regularly taking omega-3 supplements. Regular use of omega-3 supplements was associated with a higher average omega-3 Index (9.8±3.7, n=44 compared to 8.0±3.0, n=203, p=0.001 in those not taking supplements). Conclusion: This study indicates that Australian adolescents, even when from advantaged homes, have a high probability of below optimum omega-3 levels. As reduced omega-3 levels are linked to conditions of public health concern such as diabetes, asthma and depression, targeted strategies to improve the omega-3 status in the childhood population may be warranted.]]> Wed 11 Apr 2018 14:39:31 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12572 Wed 11 Apr 2018 14:04:33 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14801 Wed 11 Apr 2018 12:26:36 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22756 Wed 11 Apr 2018 09:39:12 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32707 Thu 12 Jul 2018 11:51:23 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19481 Sat 24 Mar 2018 08:02:19 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19402 Sat 24 Mar 2018 07:52:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25886 Sat 24 Mar 2018 07:25:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:4768 Sat 24 Mar 2018 07:20:41 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39180 n = 29/32) were included in the current analysis (male: n = 22, 36.07%). DHA-enriched fish oil supplementation increased total testosterone levels in males after adjusting for baseline levels, age and BMI. There was no treatment effect in females. Changes in testosterone levels in males were positively associated with changes to omega-3 PUFAs EPA and DHA and inversely correlated with omega-6 PUFA, arachidonic acid and dihomo-gamma-linolenic acid content in erythrocyte membranes, and was associated with beneficial changes to fasting insulin and HOMA-IR across the course of the study. DHA-enriched fish oil supplementation increases testosterone levels in overweight and obese men. Further research is warranted to substantiate these findings with a larger sample size and a longer follow-up period.]]> Mon 23 May 2022 16:16:26 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35691 Fri 25 Oct 2019 12:03:12 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39169 n = 38) or 2 g corn oil (CO) /day (control, n = 35) for 12 weeks in a double-blind randomised controlled trial. A fasting blood sample was collected at 0 and 12 weeks for assessment of IR, glucose and blood lipid profile. Sixty-eight participants completed the intervention. Compared with CO (n = 32), FO (n = 36) significantly reduced fasting insulin by -1.62 μIU/L (95%CI: -2.99, -0.26,) (p = 0.021) and HOMA-IR by -0.40 units (95%CI: -0.78, -0.02, p = 0.038). Higher insulin and HOMA-IR at baseline were associated with greater reductions in the FO group (p < 0.001). There was no interaction between sex and treatment for the change in insulin (p-interaction_{sex*treatment} = 0.816) or HOMA-IR (p-interaction_{sex*treatment} = 0.825). DHA-enriched FO reduces IR in adults with abdominal obesity, however, sex-dependent differences were not evident in this study.]]> Fri 20 May 2022 16:31:18 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35703 94 cm) were randomly allocated to consume fish oil (total daily dose: 1728 mg marine triglycerides, of which 588 mg EPA and 412 mg DHA, combined with 200 mg antioxidant, coenzyme Q10) or placebo (olive oil capsules) daily for 12 weeks. Liver fat was assessed using proton magnetic resonance spectroscopy. All outcomes were assessed at baseline and following 6 and 12 weeks of supplementation. Baseline liver fat was 4.6 ± 0.5% (range: 0.6 to 18.2%); 16 (32%) participants met the criteria for NAFLD (>5.5% liver fat). Repeated measures ANOVA revealed no significant time or group × time effect for fish oil versus placebo for liver fat, liver enzymes, anthropometry, or body composition including VAT (p > 0.05 for all), with similar finding for sub-analysis of participants with NAFLD. Omega-3 PUFA did not appear to be an effective agent for reducing liver fat in overweight men. The factors determining the health benefits of omega-3 PUFA supplementation on an individual level need to be clarified.]]> Fri 03 Dec 2021 10:33:51 AEDT ]]>